A Phase Ib Study of TQ05105 Tablets for the Treatment of Intermediate and High Risk Myelofibrosis Refractory/Relapsed/Intolerant to Ruxolitinib
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Rovadicitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 02 May 2024 New trial record